Ovarian cancer vaccine - Life Research Technologies

Drug Profile

Ovarian cancer vaccine - Life Research Technologies

Alternative Names: Autologous TERT-mRNA survivin peptide-loaded dendritic cell vaccine - CELLMED; Procure; TERT-mRNA and survivin-peptide double loaded dendritic cells

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LIFE RESEARCH Technologies
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 11 Mar 2017 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease, Adjuvant therapy) in Austria and Hungary (Intradermal)
  • 11 Apr 2016 Life Research Technologies plans a phase IIb trial for Ovarian cancer (Recurrent, Late-stage disease) in Germany (CELLMED website)
  • 30 Sep 2010 Phase-I/II clinical trials in Ovarian cancer in Austria (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top